Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PolyTope
- Development stage
- Preclinical
- Lead developer
- ImmunoPrecise Antibodies
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
PolyTope is a therapeutic antibody cocktail developed by ImmunoPrecise Antibodies Ltd using their PolyTope mAb Therapy platform, which employs a defined combination of monoclonal antibodies targeting multiple epitopes and mechanisms of viral evasion on SARS-CoV-2. Designed as a universal COVID-19 therapy, it aims to treat severely ill patients and provide protection, leveraging AI-driven optimization from partner EVQLV for antibody sequence selection. The program has faced production delays, with manufacturing collaboration involving ChemPartner Biologics.[6][8][10][12][14][16]
- Other names
- PolyTope mAb TherapyPolyTope TATX-03
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on PolyTope.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PolyTope.